Anti-CSF1 antibody in combination with temozolomide chemotherapeutic agent induces a wider tumor cell death efficiency with an increase in caspase3 positive tumor cells (E.) (50µm depth stack) (n=6 mice per group). Statistical analysis: D.E. one-way ANOVA followed by multiple comparisons Tukey's test. Error bars: meanSD. Scale bars: 300µm 